Benling Xu

机构：Apple (Israel), Zhengzhou University, Henan Cancer Hospital

发表论文 15 篇 · 总被引 86 次 · h-index 5

代表论文

• The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer (2023 · Cancer Biology and Medicine · 被引 23)
• High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study (2022 · Frontiers in Immunology · 被引 15)
• Generation of TALEN-mediated FH knockout rat model (2016 · Oncotarget · 被引 14)
• In vivo growth of subclones derived from Lewis lung carcinoma is determined by the tumor microenvironment. (2022 · PubMed · 被引 12)
• CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma (2024 · Molecular Immunology · 被引 6)
• Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer (2022 · Frontiers in Oncology · 被引 5)